Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, departures and layoffs occurring across the healthcare industry.
Illumina sues former employees turned founders of Guardant Health
DNA sequencing power house Illumina sued liquid biopsy company Guardant Health, whose founders used to work for Illumina, claiming the two stole information from Illumina to file patents for Guardant. Illumina alleges that one of the executives misappropriated confidential information while he was still on Illumina's payroll.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Investor insights: Ling Wong of Sea Lane Ventures and Lightspeed Venture Partners
What draws investors to healthcare startups? In this series in the runup to MedCity INVEST in Chicago, we'll highlight these perspectives. If you're a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
String of FDA approvals gives momentum to liquid biopsies
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
Guardant scores FDA approval for liquid biopsy test
In a phone interview, Guardant Health CEO Helmy Eltoukhy said he expected the approval to encourage coverage by those payers still on the sidelines.
Study finds Guardant’s liquid biopsy adept at detecting biomarker used by Merck immunotherapy drug
The study, by US and Korean researchers, found Guardant360's detection of MSI-H/dMMR "highly concordant" with that of standard tissue biopsy, including in a subset of gastric cancer patients who responded to immunotherapy.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Freenome nabs $160M to advance blood-based colorectal cancer test
The South San Francisco company intends to use the funding to launch its pivotal trial for its blood-based colorectal cancer screening and submit its test for parallel review for CMS coverage.
Guardant Health study shows liquid biopsy picking up more mutations, delivering faster results
An investment analyst wrote that physicians see the results as potentially ushering in a "liquid-first" testing paradigm, but the liquid biopsy market is likely to include several or even more than a dozen major players.
Science 37 bolsters executive team as rumors of massive Softbank investment swirl
Judy Smythe, Bardia Akbari and Niv Caviar have been named as the company's chief operating officer, senior vice president of clinical operations and chief financial officer, respectively.
Liquid biopsy firm Guardant Health files for $100M IPO
The company, which has already raised more than $500 million in venture capital funding, would trade on the NASDAQ under the ticker symbol "GH."
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Biopharma 1H18 Series A investment exceeds funding for all of 2017
Investment could be called frothy, but hasn't reached bubble territory yet, SVB report author says.
These 10 companies received 38% of digital health investment funding in 2016
In a new analysis, Accenture dives deeper into digital health funding. The assessment includes a prediction that annual investment in digital health startups will reach $7 billion by the end of 2017.
Liquid biopsy, molecular testing vs. reimbursement: A personal story
A family member's liquid biopsy test, gene testing and a journey into coverage decisions and clinical guidelines reveal how difficult the reimbursement path is for these emerging technologies.
With $360M in new financing, Guardant Health prepares to sequence one million cancer patients
Guardant Health has unveiled an ambitious five-year plan to sequence tumor DNA from one million cancer patients. Dubbed "Guardant 1 million," the push will be financed with $360 million in new financing from a broad syndicate of investors.
Guardant Health announced an almost $100M Series D round for its cancer blood test
The Redwood City, Calif.-based company has raised nearly $100 million in Series D financing led by OrbiMed Advisors.